171
Participants
Start Date
October 31, 2013
Primary Completion Date
November 30, 2018
Study Completion Date
March 31, 2019
Eflornithine
Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]
Eflornithine Placebo
Eflornithine placebo \[three tablets orally once a day\]
Sulindac 150 MG
Sulindac \[one tablet orally once a day\]
Sulindac placebo
Sulindac placebo \[one tablet orally once a day\]
UZ Leuven, Leuven
University of Pennsylvania, Philadelphia
Emory University, Atlanta
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
University Hospital Bonn, Bonn
Mayo Clinic, Rochester
Washington University, St Louis
MD Anderson Cancer Center, Houston
University of Utah- Huntsman Cancer Institute, Salt Lake City
University of California San Diego, La Jolla
Dana Farber Cancer Institute, Boston
Zane Cohen Centre For Digestive Diseases, Toronto
Academic Medical Centre, Amsterdam
Institut de Malalties Digestives, Barcelona
Institute of Genetic Medicine, Newcastle upon Tyne
Manchester Center for Genomic Medicine, Manchester
Lead Sponsor
Cancer Prevention Pharmaceuticals, Inc.
INDUSTRY